Aquestive Therapeutics Inc (AQST)

Apr 9, 2025, 7:00 AM EDT - 14 days ago

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Mar 25, 2025, 8:35 AM EDT - 4 weeks ago

Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy

Mar 6, 2025, 12:25 PM EST - 6 weeks ago

Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 4:01 PM EST - 7 weeks ago

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 12, 2025, 7:00 AM EST - 2 months ago

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Jan 6, 2025, 12:13 AM EST - 3 months ago

Aquestive Therapeutics: Five Foci For 2025

Nov 9, 2024, 8:00 AM EST - 5 months ago

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics +

ABG GSAT WLKP XMTR

Nov 5, 2024, 3:57 PM EST - 6 months ago

Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 2:09 PM EST - 6 months ago

Aquestive: Rare Opportunity With Dual Platform Strategy

Nov 4, 2024, 4:36 PM EST - 6 months ago

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 27, 2024, 8:30 AM EDT - 7 months ago

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

Sep 9, 2024, 8:15 AM EDT - 8 months ago

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

Aug 22, 2024, 11:37 PM EDT - 8 months ago

Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings

Aug 22, 2024, 8:00 AM EDT - 8 months ago

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 20, 2024, 4:12 AM EDT - 8 months ago

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 7, 2024, 2:37 PM EDT - 9 months ago

Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:22 PM EDT - 9 months ago

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 25, 2024, 8:00 AM EDT - 9 months ago

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

Jul 23, 2024, 8:00 AM EDT - 9 months ago

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

Jun 27, 2024, 8:00 AM EDT - 10 months ago

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 3, 2024, 8:00 AM EDT - 11 months ago

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

May 9, 2024, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

May 8, 2024, 12:32 PM EDT - 1 year ago

Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:19 PM EDT - 1 year ago

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 12, 2024, 4:01 PM EDT - 1 year ago

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

Apr 9, 2024, 1:25 AM EDT - 1 year ago

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

Mar 19, 2024, 9:49 PM EDT - 1 year ago

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

Mar 14, 2024, 5:23 PM EDT - 1 year ago

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

Mar 6, 2024, 10:11 AM EST - 1 year ago

Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 5:05 PM EST - 1 year ago

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Feb 21, 2024, 8:00 AM EST - 1 year ago

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Feb 15, 2024, 8:00 AM EST - 1 year ago

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

Jan 30, 2024, 8:00 AM EST - 1 year ago

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

Jan 19, 2024, 5:05 PM EST - 1 year ago

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Dec 5, 2023, 8:00 AM EST - 1 year ago

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

Nov 10, 2023, 8:00 AM EST - 1 year ago

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

Nov 7, 2023, 1:39 PM EST - 1 year ago

Aquestive Therapeutics, Inc. (AQST) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 4:37 PM EST - 1 year ago

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics Completes $45 Million Debt Refinancing

Oct 9, 2023, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics Provides Business Update

Sep 22, 2023, 7:18 PM EDT - 1 year ago

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both

SPRY

Sep 20, 2023, 9:04 AM EDT - 1 year ago

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

Aug 8, 2023, 10:45 AM EDT - 1 year ago

Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 4:01 PM EDT - 1 year ago

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 2, 2023, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

Jul 25, 2023, 8:37 PM EDT - 1 year ago

Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem

Jul 25, 2023, 4:01 PM EDT - 1 year ago

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

Jul 25, 2023, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference